

PX'Therapeutics to open a new cGMP biomanufacturing facility

Grenoble, France, November 23rd 2009 – PX'Therapeutics SA (formerly known as Protein'eXpert) announces the set up of an additional biomanufacturing unit dedicated to the production of therapeutic proteins and monoclonal antibodies in mammalian cells. This facility, located in the company's Grenoble site, is mainly financed by loans from PX'Therapeutics' bank partners: BNP Paribas and Crédit Coopératif, with the support of OSEO Rhône-Alpes. The cGMP plant will be operational from April 2010 and will allow cell banking as well as preclinical and clinical manufacturing of biotherapeutics (scale: 100-200L). In parallel, PX'Therapeutics plans to upgrade the existing cGMP unit devoted to bacterial and yeast systems with a 100L bioreactor. The extension of the company's production capabilities is part of its development strategy and will mark its tenth anniversary. Indeed, PX'Therapeutics is anticipating strong growth in the next two years, mainly due to the strengthening of its commercial activities in Europe and North America, the set up of new partnerships with big pharmas and the creation of value out of collaborative R&D programs focused on biotherapeutics/vaccine development.

About PX'Therapeutics

PX'Therapeutics, located in Grenoble and Lyon (France) and with a sales office in Cambridge (MA, USA), offers early stage research and cGMP manufacturing contracts focusing on the development of protein therapeutics, monoclonal antibodies and recombinant vaccines. PX'Therapeutics proposes custom programs targeting the generation of murine antibodies, humanization of therapeutic antibodies, protein engineering and optimization, feasibility studies, process development or small scale clinical manufacturing.

PX'Therapeutics has been playing a key role in the discovery, development and production of target or therapeutic proteins, with over 500 projects performed so far. The company has then accumulated a specific and acknowledged expertise in the field of difficult-to-express proteins and developed trusted relationships with more than 140 biotech/pharmaceutical partners and clients in Europe, North America and Japan.

As an example, in 2009, two therapeutic candidates developed by PX'Therapeutics have produced positive results as part of Phase I clinical trials performed in Europe and in the United States.

Contact

Christelle Dagoneau

Business Development Director

+33 4 38 02 36 50

ChristelleDagoneau@px-therapeutics.com

www.px-therapeutics.com